News und Analysen

Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before

Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before

A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high

A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high

A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs

Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs

As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint

As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint

As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares trade around $62. At Friday's prices, a paltry $100 investment in 2022 would

Nvidia (NASDAQ: NVDA) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a

With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could

With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could

With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could

A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its

A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its

Shares of Medtronic (NYSE: MDT) responded poorly to the company's latest quarterly results announcement. The market knocked the stock about 5% lower on May 23, but some analysts who follow the

The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future

The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future

The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future

When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We